產品資料
產品[

CRL-2558 PL45 人胰腺導管腺癌細胞

]資料
如果您對該產品感興趣的話,可以 sendmsg
產品名稱: CRL-2558 PL45 人胰腺導管腺癌細胞
產品型號: CRL-2558
產品廠商: 美國標準生物品收藏中心（ATCC）
產品文檔: 無相關文檔


簡單介紹

CRL-2558 PL45 人胰腺導管腺癌細胞，原代細胞|細胞系|細胞株|菌種；細胞庫管理規(guī)范，提供的細胞株背景清楚，提供參考文獻和培養(yǎng)條件！

CRL-2558 PL45 人胰腺導管腺癌細胞 的詳細介紹
CRL-2558 PL45 人胰腺導管腺癌細胞
ATCC® Number: CRL-2558™    Price: $329.00
Designations: PL45
Depositors:  SE Kern
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens (human)
Morphology: epithelial
Source: Organ: pancreas
Disease: ductal adenocarcinoma
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
 
Oncogene: BRCA2 +; DPC4 +; K-ras +; p53 +
DNA Profile (STR): Amelogenin: X
CSF1PO: 12
D13S317: 12
D16S539: 9,12
D5S818: 13
D7S820: 8,9
THO1: 6,9.3
TPOX: 11
vWA: 16
Age: *****
Gender: male
Ethnicity: White
Comments: PL45 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the pancreas of a man with poorly differentiated pancreatic adenocarcinoma of ductal origin.
The MTS1 gene on chromosome 9p21 encodes the p16 inhibitor of cyclinD/CDK4 complexes. PL45 cells have a wild-type p16 gene. [50656]
This gene is transcriptionally silenced and methylated in PL45 cells.
PL45 cells have a wild-type cyclin-dependent kinase (CDK4) gene.
Both the PL45 and the Panc 10.05 cell lines exhibit a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655] [50656]
The line expresses wild-type DPC4 and BRCA2 genes.
The line has a p53 gene mutation at codon 255 where an ATC --> AAC mutation resulted in substitution of asparagine for isoleucine.
The PL45 cell line was derived from the same patient as the Panc 10.05 cell line (ATCC CRL-2547).
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol:
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
derived from same individual:ATCC CRL-2547
References: 50655: Jaffee EM, et al. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J. Sci. Am. 4: 194-203, 1998. PubMed: 9612602
50656: Caldas C, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet. 8: 27-32, 1994. PubMed: 7726912
51521: Su GH, et al. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc. Natl. Acad. Sci. USA 98: 3254-3257, 2001. PubMed: 11248065
ATCC® Number: CRL-2558™ Price: $329.00
Designations: PL45
Depositors: SE Kern
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens (human)
Morphology: epithelial


Source: Organ: pancreas
Disease: ductal adenocarcinoma
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Oncogene: BRCA2 +; DPC4 +; K-ras +; p53 +
DNA Profile (STR): Amelogenin: X
CSF1PO: 12
D13S317: 12
D16S539: 9,12
D5S818: 13
D7S820: 8,9
THO1: 6,9.3
TPOX: 11
vWA: 16
Age: *****
Gender: male
Ethnicity: White
Comments: PL45 is a pancreatic adenocarcinoma epithelial cell line derived in 1992 from a primary tumor removed from the pancreas of a man with poorly differentiated pancreatic adenocarcinoma of ductal origin.
The MTS1 gene on chromosome 9p21 encodes the p16 inhibitor of cyclinD/CDK4 complexes. PL45 cells have a wild-type p16 gene. [50656]
This gene is transcriptionally silenced and methylated in PL45 cells.
PL45 cells have a wild-type cyclin-dependent kinase (CDK4) gene.
Both the PL45 and the Panc 10.05 cell lines exhibit a K-ras oncogene mutation at codon 12 where a GGT --> GAT mutation resulted in substitution of aspartic acid for glycine. [50655] [50656]
The line expresses wild-type DPC4 and BRCA2 genes.
The line has a p53 gene mutation at codon 255 where an ATC --> AAC mutation resulted in substitution of asparagine for isoleucine.
The PL45 cell line was derived from the same patient as the Panc 10.05 cell line (ATCC CRL-2547).
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol:
1.Remove and discard culture medium.
2.Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
3.Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
4.Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
5.Add appropriate aliquots of the cell suspension to new culture vessels.
6.Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC
產品留言
標題
聯系人
聯系電話
內容
驗證碼
點擊換一張
注：1.可以使用快捷鍵Alt+S或Ctrl+Enter發(fā)送信息!
2.如有必要,請您留下您的詳細聯系方式!

聯系我們
產品搜索

細胞系，ATCC細胞，ATCC菌種，細胞系目錄，ATCC，鼠傷寒沙門氏菌，atcc細胞庫，人**瘤細胞，人食管癌細胞，ATCC 19404，ATCC 25922，ATCC 19146，微生物菌種，細胞株，標準菌株，ATCC中國，atcc上海代理，CMCC 菌株，ATCC菌株，細胞目錄，質控菌株，腫瘤細胞株，乳腺癌細胞系，人肝癌細胞系
產品目錄

Copyright? 2003-2025  上海復祥生物科技有限公司版權所有            電話：021-35080510
傳真：021-35080520    地址：上海市虹口區(qū)赤峰路630號南雁大廈1901室    郵編： 滬ICP備10013034號-3  

  

滬公網安備 31010902002429號